Avidity Biosciences, Inc.

Equities

RNA

US05370A1088

Pharmaceuticals

Market Closed - Nasdaq 04:00:00 2024-03-01 pm EST 5-day change 1st Jan Change
20.11 USD +9.89% Intraday chart for Avidity Biosciences, Inc. +43.23% +122.21%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Apprehension About Key Inflation Data Pushes Exchange-Traded Funds, Equity Futures Lower Pre-Bell Thursday MT
Avidity Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Avidity Biosciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Avidity Biosciences Receives US FDA's Rare Pediatric Disease Designation for AOC 1044 in Duchenne Muscular Dystrophy MT
Avidity Biosciences Receives FDA Rare Pediatric Disease Designation for AOC 1044 for Treatment of Duchenne Muscular Dystrophy in People with Mutations Amenable to Exon 44 Skipping CI
Avidity Biosciences Appoints Strategy Chief, Plans to Start Phase 3 Myotonic Dystrophy Type 1 Study MT
Avidity Biosciences, Inc. Plans to Initiate the Global Phase 3 Harbour Trial of AOC 1001 for Adults Living with Myotonic Dystrophy Type 1, in Mid-2024 CI
Avidity Biosciences, Inc. Announces Resignation of Eric Mosbrooker as Board of Directors and the Human Capital Management Committee of the Board CI
Avidity Biosciences Reports Positive Data Demonstrating Aoc 1044 Delivers Unprecedented Concentrations of Pmo in Muscle Following A Single Dose in Healthy Volunteers from Phase 1/2 Explore44? Trial for Duchenne Muscular Dystrophy CI
Sector Update: Health Care Stocks Ease Tuesday Afternoon MT
Sector Update: Health Care Stocks Decline Premarket Tuesday MT
Sector Update: Health Care MT
Traders Await Economic Data as US Equity Futures Post Narrow Losses Pre-Bell MT
Avidity Biosciences Collaborates With Bristol Myers to Advance Use of AOC in Multiple Cardiac Targets MT
Bristol Myers Squibb to Take Stake in Avidity Biosciences, Expand Partnership DJ
Avidity Biosciences, Inc. Announces Expansion of Cardiovascular Collaboration with Bristol Myers Squibb for Up to Five Targets Utilizing Avidity's Proprietary AOC Platform Technology CI
Avidity Biosciences, Inc. announced that it expects to receive $39.999993 million in funding from Bristol-Myers Squibb Company CI
Wall Street Set to Open Higher Thursday as Jobless Claims Fall, Ahead of Powell Speech MT
Top Premarket Gainers MT
Avidity Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Avidity Biosciences, Inc. Presents New Data Regarding Its Clinical Study of AOC 1001 for Adults with Myotonic Dystrophy Type 1 CI
Avidity Biosciences Gets FDA Orphan Drug Label For AOC 1044 in Muscular Dystrophy MT
Avidity Biosciences Gets Orphan-Drug Status for Muscular Dystrophy Treatment DJ
Chardan Trims Price Target on Avidity Biosciences to $23 From $27, Keeps Buy Rating MT
Avidity Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Chart Avidity Biosciences, Inc.
More charts
Avidity Biosciences, Inc. is a biopharmaceutical company. The Company is engaged in delivering a new class of ribonucleic acid (RNA) therapeutics called antibody oligonucleotide conjugates (AOCs.). The Company's AOC platform is designed to combine the specificity of monoclonal antibodies (mAbs), with the precision of RNA therapeutics to target the root cause of diseases previously untreatable with RNA therapeutics. The AOC platform also has the option to deploy various types of oligonucleotides, including small interfering RNA (siRNAs) and patient measure of safety (PMOs), whose specific mechanisms of action modify RNA function in different ways. The Company's pipeline includes AOC 1001, and AOC 1020. AOC 1001 is designed to treat people with myotonic dystrophy type 1 (DM1). AOC 1020 is designed to treat people living with facioscapulohumeral.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
20.11 USD
Average target price
37.5 USD
Spread / Average Target
+86.47%
Consensus
-40% Limited-time offer: Our subscriptions help you unlock the best investment opportunities.
SIGN UP NOW